Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2023 Nov 2;18(11):e0292672. doi: 10.1371/journal.pone.0292672

Long COVID in the United States

David G Blanchflower 1,2,3,#, Alex Bryson 4,5,*,#
Editor: Kanchan Thapa6
PMCID: PMC10621843  PMID: 37917610

Abstract

Although yet to be clearly identified as a clinical condition, there is immense concern at the health and wellbeing consequences of long COVID. Using data collected from nearly half a million Americans in the period June 2022-December 2022 in the US Census Bureau’s Household Pulse Survey (HPS), we find 14 percent reported suffering long COVID at some point, half of whom reported it at the time of the survey. Its incidence varies markedly across the United States–from 11 percent in Hawaii to 18 percent in West Virginia–and is higher for women than men, among Whites compared with Blacks and Asians, and declines with rising education and income. It is at its highest in midlife in the same way as negative affect. Ever having had long COVID is strongly associated with negative affect (anxiety, depression, worry and a lack of interest in things), with the correlation being strongest among those who currently report long COVID, especially if they report severe symptoms. In contrast, those who report having had short COVID report higher wellbeing than those who report never having had COVID. Long COVID is also strongly associated with physical mobility problems, and with problems dressing and bathing. It is also associated with mental problems as indicated by recall and understanding difficulties. Again, the associations are strongest among those who currently report long COVID, while those who said they had had short COVID have fewer physical and mental problems than those who report never having had COVID. Vaccination is associated with lower negative affect, including among those who reported having had long COVID.

1. Introduction

The SARS-CoV-2 (or COVID) pandemic has resulted in an estimated 6.8 million deaths around the world since the beginning of the outbreak in December 2019 and severely impacted the lives of many others who suffered temporary illness [1]. Fig 1 plots the weekly estimates of COVID cases and deaths in the United States reported by the Centers for Disease Control and Prevention (CDC) [2]. These show three major spikes in cases, peaking at 5.6 million at the start of 2022. The number of deaths has four major peaks with the highest, 23,387, again at the start of 2021. The latest estimate for the start of 2023, was 415,000 cases and 3,900 deaths. However, it has become increasingly apparent that a significant proportion of the population continue to report COVID symptoms long after initial infection. This condition, which has come to be known as ‘long COVID’, has yet to be clearly identified as a clinical condition, but is defined by the World Health Organization (WHO) as the continuation or development of new symptoms three months after the initial infection, with these symptoms lasting for at least 2 months with no other explanation [3].

Fig 1. Number of COVID cases and death per week in the United States.

Fig 1

The recency of long COVID, together with difficulties in precisely defining it [4] mean uncertainty persists regarding its incidence and consequences. Notwithstanding these issues, a consensus is emerging regarding its incidence, factors associated with it, and its health consequences. We review this literature below in Section Two. We contribute to this body of work by exploiting new survey data on the incidence and consequences of long COVID in the US Census Bureau’s Household Pulse Survey (HPS) [5]. In doing so we build on an earlier paper [6] that examined the incidence of COVID and changes in mental health over the period April 2020-April 2022. That paper used data from HPS sweeps #1-#44. This paper extends that work from June through December 2022 with new data on long COVID from sweeps #46-#53 that was not available in earlier sweeps.

We find 14 percent of respondents reported suffering long COVID at some point, half of whom reported it at the time of the survey. Its incidence varies markedly across the United States–from 11 percent in Hawaii to 18 percent in West Virginia–and is higher for women than men, among Whites compared with Blacks and Asians, and declines with rising education and income. It is at its highest in midlife in the same way as negative affect. Ever having had long COVID is strongly associated with negative affect (anxiety, depression, worry and a lack of interest in things), with the correlation being strongest among those who currently report long COVID, especially if they report severe symptoms. In contrast, those who report having had short COVID report higher wellbeing than those who report never having had COVID. Long COVID is also strongly associated with physical mobility problems, and with problems dressing and bathing. It is also associated with mental problems as indicated by recall and understanding difficulties. Again, the associations are strongest among those who currently report long COVID, while those who said they had had short COVID have fewer physical and mental problems than those who report never having had COVID. Vaccination is associated with lower negative affect, including among those who reported having had long COVID.

2. Previous literature on the incidence and health effects of long COVID

In their systematic review article Davis et al. [7] define long COVID as “a multisystemic condition comprising often severe symptoms that follow a sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection” (p. 134). They say that more than 200 symptoms have been identified, with impacts on multiple organ systems. They estimate that “at least 10%” of those with severe COVID infections go on to develop long COVID. This is roughly 65 million individuals worldwide. They say many long COVID sufferers experience “dozens of symptoms across multiple organ systems” (p. 134). Among them are cognitive and physical impairments we focus on in this study.

In their systematic review of 194 studies–most of them in Europe—O’Mahoney et al. [8] showed that at an average follow-up time of 126 days, 45% of COVID survivors, regardless of hospitalization status, go on to experience at least one unresolved symptom. In addition, the prevalence of ongoing symptoms appears to be higher in post-hospitalized cohorts compared to non-hospitalized populations. Taquet et al. [9] conducted a retrospective cohort study based on linked electronic health records (EHRs) data from 81 million patients including 273,618 COVID survivors and found 57% of patients having at least one long-COVID feature recorded within the first 180 days after infection and 37% having them in the 90 to 180 days after diagnosis.

Correlates of long COVID emerging from this literature include variance by age, and a potential role for vaccination which, at least in some studies, reduced the probability of long COVID [7, p. 140]. Taquet et al. [9] found a higher incidence of long COVID among the elderly, in more severely affected patients, and in women, patterns also found by Subramanian et al. [10] among non-hospitalized adults. Qasmieh et al. [11] also found long COVID was higher among females, but also among Blacks and the unemployed. Price [12], who used the HPS as we do, found long-term COVID symptoms were much more prevalent among women, adults under 65, Hispanics and Latinos, and non–college graduates than among other demographic groups. Using a non-probability internet survey and a slightly different definition of long COVID (symptomatic two months after initial infection) Perlis et al. [13] also found a higher incidence among women. They also pointed to a lower incidence among the more highly educated and among those who had been vaccinated. Symptoms included cognitive and respiratory problems, anxiety and sleep disruption.

For the UK the Office for National Statistics calculated the incidence of long COVID from their Coronavirus (COVID) Infection Survey [14]. They estimated that 2.1 million people living in private households in the UK (3.3% of the population) were experiencing self-reported long COVID (which they defined as symptoms continuing for more than four weeks after the first confirmed or suspected COVID infection that were not explained by something else) as of 4 December 2022. Long COVID symptoms adversely impacted the day-to-day activities of 1.6 million. The prevalence was greatest in midlife ages 35–69.

Using the same ONS survey Ayoubkhani et al. [15] found the odds of long COVID symptoms decreased after COVID vaccination by around 13 percent, while a second dose reduced the odds by around 9% thus sustaining protection against long COVID. In a related study with the same survey Ayoubkhani et al. [16] find long COVID symptoms were significantly lower among those receiving 2 doses of the vaccine after 12 weeks relative to being unvaccinated when infected.

Also, for the UK, Bagues and Dimitrova [17] report psychological gains from COVID vaccination. Although their paper is not focused on long COVID, it is notable in using exogenous variance in the timing of vaccination roll-out to make causal inferences about the positive impact of COVID vaccination in increasing psychological wellbeing as captured by a reduction in the General Health Questionnaire short form (GHQ-12) scale capturing mental distress.

Notwithstanding differences in the precise definition of long COVID, survey design and populations, taken together, these previous studies indicate that long COVID is a common condition among those infected with the virus, although its incidence varies across demographic groups. It often comes with multiple symptoms which can be severe and affect both cognitive and physical function.

In the next section of the paper we describe our data and methods. In the subsequent section we present the incidence of long COVID in the population of the United States, and its incidence across sub-populations before estimating the probability of long COVID, thus identifying the independent correlations with a number of individual traits, as well as location and vaccination status. In the final part of Section Four we establish the association between long COVID and cognitive and physical impairment as well as ill-being. Section Five concludes.

3. Data and methods

Our data are the United States Census Bureau’s Household Pulse Survey (HPS) for the period January through December 2022 [5]. The HPS was designed to obtain data on how people’s lives had been impacted by COVID in a quick and efficient manner. It does so with a short on-line survey. These sweeps of the data include new data on long COVID from sweeps June 2022 onwards (sweeps #46-#53) that was not available in earlier sweeps [18]. The data we examine here on long COVID is from sweeps #46 (Jun 1-Jun 13, 2022);, #47 (June 29-July 11, 2022);; #48 (July 27-Aug 8, 2022);; #49 (Sept 14-Sept 26, 2022);; #50 (Oct 5-Oct 17, 2022); #51 (Nov 2-Nov 14, 2022);, #52 (Dec 9-Dec 19, 2022); and #53 (Jan 4–16, 2023). They form part of an extended battery of 14 questions on COVID infection (see S1 Appendix). The sample size is 461,550.

The data are publicly available and can be downloaded here: https://www.census.gov/programs-surveys/household-pulse-survey/datasets.html The accompanying technical documentation can be found here: https://www.census.gov/programs-surveys/household-pulse-survey/technical-documentation.html

In Section Four we report simple descriptive statistics establishing the incidence of long COVID in the United States population. In doing so we weight the descriptive statistics with the person weight variable (PWEIGHT) provided by the US Census to account for non-response biases. We then run regression analyses to establish the correlates of long COVID, long COVID experienced now, and long COVID with substantial symptoms, using unweighted data. All three are (0,1) outcomes and so are estimated with probit regressions. We then turn to the association between long COVID now and in the past on four negative affect measures with ordinal responses, so we estimate the long COVID effect using ordinal logits. A composite negative affect metric adding up the scores on the four separate negative affect measures is estimated with Ordinary Least Squares (OLS) estimation.

4. Results

4.1: Incidence of long COVID and long COVID symptoms in the US Census HPS

Whereas almost half (46.7%) of respondents say they have had COVID at some point (‘yes’ to Q2 in S1 Appendix) only 14.4% said they had ever had COVID symptoms lasting 3 months or longer (Q3). This suggests that around three-in-ten of those who get COVID go on to develop long COVID. There were 6,844 unclassified, unweighted cases due to missing values and 59,505 (unweighted) cases with long COVID of whom 29,839 had symptoms now.

The survey prompted respondents as to what long term symptoms they may have, prompting them with the following description:

Did you have any symptoms lasting 3 months or longer that you did not have prior to having coronavirus or COVID? Long term symptoms may include—tiredness or fatigue, difficulty thinking, concentrating, forgetfulness, or memory problems (sometimes referred to as "brain fog", difficulty breathing or shortness of breath, joint or muscle pain, fast-beating or pounding heart (also known as heart palpitations), chest pain, dizziness on standing, menstrual changes, changes to taste/smell, or inability to exercise? (Q1)

Those who had had COVID were asked about the severity of their symptoms. 13.3% said they had suffered “severe symptoms” (S1 Appendix, Question 5). Table 1 shows how severe the symptoms of COVID were for those who had had short COVID–that is, COVID symptoms lasting less than 3 months—and those who reported long COVID now and in the past. Of those with short COVID only 7% had severe symptoms compared with 24% for those who had had long COVID in the past and 31% who currently had long COVID. Even so, this means two-thirds of those with long COVID now were not suffering severe symptoms.

Table 1. The distribution of symptoms (n = unweighted; figures are weighted column percentages).

No COVID Short COVID Long COVID Long COVID All
not now now N
No COVID 53 244,414
No symptoms 8 3 2 3 10,382
Mild symptoms 47 26 21 19 85,826
Moderate symptoms 38 48 46 19 88,652
Severe symptoms 7 24 31 6 24,189
All row % 53 33 8 7
N 244,414 149,732 29,510 29,807 453,463 453,463

In sweeps #49-#53 which cover the period September 14 2022 to January 16 2023—a further question was asked of those with long COVID–Q6. Do these long-term symptoms reduce your ability to carry out day-to-day activities compared with the time before you had COVID? The sample size across these five sweeps is 288,951. 6.9% of weighted respondents currently reporting long COVID also reported such symptoms (Longnow). We decided to classify as Longlot those who said they had long COVID now and their symptoms reduced their ability to carry out day-to-day activities ’a lot’. Overall, 1.6% of the sample from weeks 49–53 or a quarter of those who say they have COVID, now have major debilitating issues.

Our finding that 6.9% had long COVID with current symptoms is consistent with results from a recent paper by McKaylee et al. [19] who estimated the prevalence of long COVID from June 30-July 2, 2022, in a random sample of 3,042 adults from the US population. They found 7.3% reporting long COVID.

Table 2 presents means for ever having had long COVID (LongCOVID) and currently having long COVID with current symptoms (Longnow) in parentheses for the whole of the United States and for sub-populations. The patterns are similar for both. The incidence of long COVID is greatest in midlife, it is higher for women (as found by Chen et al. [20]) and declines with education and income. Long COVID is also more prevalent among whites than blacks or Asians. There is substantial regional variance across States: Hawaii has lowest incidence and West Virginia highest.

Table 2. Weighted mean proportion with long COVID and long COVID now with symptoms.

USA 14.4 (6.9) Michigan 13.8 (6.7)
Men 11.1 (5.0) Minnesota 13.3 (6.5)
Women 17.6 (8.7) Mississippi 17.6 (8.3)
Age <30 15.8 (6.4) Missouri 14.7 (7.4)
Age 30–39 16.4 (7.4) Montana 15.8 (8.7)
Age 40–49 17.6 (8.3) Nebraska 14.3 (6.6)
Age 50–59 15.9 (8.1) Nevada 15.3 (6.9)
Age 60–69 11.2 (6.1) New Hampshire 12.6 (6.5)
Age 70–79 7.9 (4.5) New Jersey 13.1 (6.3)
Age 80+ 6.4 (3.5) New Mexico 15.8 (7.5)
Hispanic 18.6 (7.6) New York 14.5 (6.8)
Asian 9.8 (4.0) North Carolina 14.6 (6.8)
Black 12.8 (5.7) North Dakota 15.9 (7.7)
Non-Hispanic white 13.8 (7.0) Ohio 13.7 (7.1)
Non-Hispanic other 18.0 (9.0) Oklahoma 17.1 (8.1)
Less than high school 16.5 (9.6) Oregon 13.1 (6.5)
High school diploma 14.3 (6.4) Pennsylvania 12.8 (5.5)
Some college 16.9 (8.4) Rhode Island 13.8 (7.0)
Bachelor’s degree 12.5 (6.1) South Carolina 15.0 (7.8)
Graduate degree 10.4 (5.1) South Dakota 15.8 (7.7)
Working 15.2 (7.1) Tennessee 16.8 (8.3)
Not working 13.5 (6.6) Texas 15.3 (7.1)
Alabama 17.5 (8.8) Utah 16.4 (8.0)
Alaska 16.8 (7.7) Vermont 10.8 (5.9)
Arizona 16.6 (7.9) Virginia 12.1 (5.7)
Arkansas 17.4 (8.6) Washington 12.5 (6.7)
California 14.0 (6.7) West Virginia 18.2 (9.3)
Colorado 15.8 (7.3) Wisconsin 13.8 (6.9)
Connecticut 13.2 (6.7) Wyoming 18.0 (8.3)
Delaware 11.5 (6.2) Vaccinated 14.2 (6.9)
District of Columbia 9.8 (5.1) Less than $25,000 16.5 (8.0)
Florida 13.7 (6.2) $25,000 - $34,999 16.9 (8.6)
Georgia 14.6 (6.9) $35,000 - $49,999 16.2 (8.2)
Hawaii 11.0 (4.0) $50,000 - $74,999 15.2 (7.5)
Idaho 16.2 (8.3) $75,000 - $99,999 14.5 (7.2)
Illinois 14.2 (6.5) $100,000 - $149,999 13.4 (6.6)
Indiana 15.8 (7.6) $150,000 - $199,999 11.8 (5.9)
Iowa 14.6 (7.7) $200,000 and above 9.3 (4.3)
Kansas 14.8 (7.0)
Kentucky 15.9 (8.4) Figures in parentheses % long COVID now.
Louisiana 16.1 (7.3)
Maine 12.0 (6.4)
Maryland 12.2 (5.6)
Massachusetts 12.7 (6.1)
Michigan 13.8 (6.7)

The CDC has reported the incidence of long COVID using these data for each of the seven surveys we examine. They found the incidence higher among women, the prime age, Hispanics and high school dropouts and highest in West Virginia, Wyoming, Mississippi and Kentucky and lowest in Vermont and Rhode Island. https://www.cdc.gov/nchs/COVID19/pulse/long-COVID.htm

4.2: The probability of having long COVID

To establish independent associations between long COVID and individuals’ characteristics we run a set of probit estimates in Table 3. The covariates entering the estimates are: age (15 bands), race (5 categories), male, education (7 categories), whether the respondent was working, state of residence and week of interview.

Table 3. Probit estimates of long COVID, long COVID with symptoms now and ever had COVID 2022.

Long COVID Longnow Longlot
20–24 .2133 (5.54) .2489 (4.72) .3988 (3.19)
25–29 .2190 (5.88) .2557 (4.99) .3496 (2.84)
30–34 .2331 (6.31) .2887 (5.68) .4032 (3.31)
35–39 .2534 (6.89) .3447 (6.81) .4858 (4.00)
40–44 .2853 (7.76) .3871 (7.66) .5428 (4.48)
45–49 .2886 (7.84) .4269 (8.44) .6134 (5.07)
50–54 .2565 (6.97) .4039 (7.99) .5815 (4.80)
55–59 .1904 (5.17) .3591 (7.10) .5808 (4.80)
60–64 .0671 (1.82) .2735 (5.41) .4725 (3.91)
65–69 -.0766 (2.08) .1350 (2.66) .2559 (2.11)
70–74 -.1707 (4.57) .0538 (1.05) .1493 (1.22)
75–79 -.2412 (6.27) -.0074 (0.14) .1347 (1.08)
80–84 -.2469 (5.91) -.0010 (0.02) .2040 (1.57)
85–89 -.2605 (5.30) -.0195 (0.31) .3022 (2.16)
Male -.2883 (56.70) -.2833 (15.14) -.1744 (12.96)
Some high school -.0277 (0.80) -.1429 (3.37) -.2329 (3.26)
High school graduate -.0351 (1.20) -.0875 (2.50) -.2987 (5.16)
Some college .0290 (1.01) .0145 (0.42) -.2119 (3.74)
Associate degree .0290 (0.99) .0136 (0.39) -.2220 (3.83)
Bachelor degree -.1692 (5.86) -.1480 (4.28) -.4124 (7.24)
Graduate degree -.2462 (8.49) -.2108 (6.07) -.4390 (7.63)
Black -.2305 (18.34) -.1728 (11.02) -.0875 (2.65)
Asian -.3396 (22.09) -.2961 (14.89) -.2541 (5.43)
Other -.0007 (0.06) .0918 (5.69) .1986 (6.14)
White non-Hispanic -.1665 (17.75) -.0652 (5.60) -.0542 (2.17)
Work .0020 (0.35) -.0199 (2.84) -.2848 (19.76)
Alaska -.1358 (4.81) -.1229 (3.62) -.2285 (3.17)
Arizona -.1627 (6.62) -.1638 (5.52) -.1929 (3.11)
Arkansas -.0309 (1.13) -.0453 (1.38) .0152 (0.24)
California -.2602 (11.91) -.2157 (8.22) -.2009 (3.71)
Colorado -.1497 (6.04) -.1411 (4.72) -.1823 (2.87)
Connecticut -.2067 (7.51) -.1433 (4.36) -.1299 (1.88)
Delaware -.2364 (7.36) -.1866 (4.84) -.1352 (1.71)
DC -.4132 (13.34) -.3234 (8.59) -.2843 (3.45)
Florida -.2101 (8.72) -.1997 (6.86) -.1502 (2.51)
Georgia -.1545 (6.18) -.1407 (4.66) -.2096 (3.24)
Hawaii -.3372 (10.40) -.3504 (8.66) -.3582 (4.07)
Idaho -.0872 (3.35) -.0748 (2.40) -.0773 (1.24)
Illinois -.1821 (7.11) -.1715 (5.53) -.1839 (2.80)
Indiana -.0962 (3.67) -.1138 (3.59) -.0907 (1.39)
Iowa -.1504 (5.64) -.1214 (3.79) -.1294 (1.95)
Kansas -.1251 (4.81) -.1351 (4.30) -.1645 (2.47)
Kentucky -.0972 (3.60) -.0797 (2.46) -.2369 (3.35)
Louisiana -.0708 (2.53) -.1118 (3.27) -.0350 (0.52)
Maine -.2503 (7.95) -.1986 (5.26) -.2161 (2.68)
Maryland -.2683 (10.25) -.2537 (7.95) -.2746 (3.97)
Massachusetts -.2397 (9.54) -.2122 (6.99) -.1798 (2.79)
Michigan -.1538 (6.30) -.1401 (4.77) -.0911 (1.53)
Minnesota -.2179 (8.50) -.1799 (5.84) -.1657 (2.56)
Mississippi .0051 (0.18) -.0118 (0.34) -.0971 (1.36)
Missouri -.1454 (5.54) -.1158 (3.68) -.0827 (1.29)
Montana -.0546 (1.90) -.0664 (1.92) .0177 (0.27)
Nebraska -.1372 (5.13) -.1588 (4.88) -.2596 (3.68)
Nevada -.1435 (5.17) -.1341 (4.01) -.2307 (3.16)
New Hampshire -.2063 (7.30) -.1670 (4.93) -.1448 (2.02)
New Jersey -.1733 (6.45) -.1438 (4.44) -.1626 (2.36)
New Mexico -.1668 (6.26) -.1310 (4.10) -.1694 (2.57)
New York -.1521 (5.70) -.1443 (4.47) -.1726 (2.50)
North Carolina -.1723 (6.44) -.1327 (4.14) -.0952 (1.44)
North Dakota -.0823 (2.71) -.1144 (3.09) -.1780 (2.27)
Ohio -.1619 (6.01) -.1374 (4.24) -.1246 (1.85)
Oklahoma -.0426 (1.63) -.0584 (1.86) -.0884 (1.38)
Oregon -.2712 (10.90) -.2282 (7.63) -.1550 (2.53)
Pennsylvania -.2189 (8.73) -.2097 (6.90) -.1845 (2.89)
Rhode Island -.1624 (4.98) -.1346 (3.43) -.1726 (2.08)
South Carolina -.1059 (3.92) -.1013 (3.12) -.1131 (1.68)
South Dakota -.0945 (3.23) -.0945 (2.68) -.1020 (1.41)
Tennessee -.0434 (1.68) -.0308 (1.00) -.0776 (1.21)
Texas -.1824 (8.13) -.1643 (6.08) -.1361 (2.47)
Utah -.1028 (4.22) -.0950 (3.24) -.0813 (1.35)
Vermont -.3122 (9.63) -.2118 (5.53) -.2112 (2.51)
Virginia -.2902 (11.57) -.2484 (8.19) -.2105 (3.32)
Washington -.2943 (12.62) -.2113 (7.58) -.1239 (2.19)
West Virginia .0232 (0.80) .0280 (0.81) .0097 (0.14)
Wisconsin -.1885 (7.08) -.1737 (5.39) -.2187 (3.16)
Wyoming -.0352 (1.21) -.0463 (1.33) -.0968 (1.34)
Constant -.7674 -1.3302 -1.8703
Pseudo R2 .0406 .0309 .0419
N 448,227 448,119 285,954

Notes: Reference categories are: Alabama; less than high school; age<20 and white Hispanic. T-statistics in parentheses. Controls also include week of interview. Pseudo R2 is a measure of model fit. Longlot only available in weeks #49-#53

In column 1 of Table 3 we estimate a probit equation for the (0,1) outcome that an individual has ever had long COVID (LongCOVID). The second column presents probit estimates for the (0,1) outcome of having long COVID now with symptoms (Longnow). The final column reports estimates for the (0,1) outcome of long COVID now with symptoms that reduce one’s ability to carry out day-to-day activities ’a lot’ (Longlot). The sample size is smaller for the final column because the question on symptoms affecting one’s ability to carry out day-to-day activities is only asked between September 14 2022 and January 16 2023.

Consistent with the existing studies, women are more likely to suffer long COVID. They are also more likely than men to report currently having long COVID with symptoms (column 2), and to have symptoms that affect them a lot (column 3). Whites are more likely to suffer long COVID than non-white ethnic groups. They are also more likely to have long COVID with symptoms and symptoms that affect their day-to-day activities ‘a lot’.

The incidence of long COVID is highest in Alabama, Mississippi and West Virginia–which are also among the states with the lowest subjective wellbeing rankings in the United States [21] whilst Hawaii—the highest ranked state on subjective wellbeing [21]–has the lowest incidence of long COVID.

The probability of long COVID falls among graduates, as does the probability of long COVID with symptoms, and with severe symptoms.

In their earlier study, Blanchflower and Bryson [6] found workers were more likely to have had COVID than non-workers. The simple descriptive means in Table 2 indicate that workers were more likely than non-workers to have had long COVID and to have long COVID with symptoms at the time of interview. However, there is no statistically significant association between working and having had long COVID in Table 3 (the coefficient in column 1 is 0.002 with a t-statistic of 0.35). Furthermore, working was negatively associated with currently having long COVID with symptoms (column 2) and currently having long COVID with symptoms that affected their day-to-day activity a lot (column 3). This may be because individuals with long COVID with symptoms felt obliged to stay away from work for fear of spreading the virus, or because they were physically unable to perform work tasks and thus forced onto temporary or long-term sickness absence.

The age structure of long COVID tracks that of the unhappiness literature peaking in midlife between the ages of 45 and 49 [22]. This contrasts with the findings in our earlier paper regarding the incidence of COVID [6] which peaked between the ages of 20–24. Long COVID incidence ever and at the time of interview peaked in mid-life.

Overall, in the sample 83.2% of respondents had received a vaccine. Of those who had not had Covid 84.2% had received a vaccine, compared with 82.0% who had had short covid and 82.1% of those who reported they at some time suffered from long covid.

4.3: The impact of long COVID on wellbeing and physical and mental health

In this section we examine the impact of long COVID and symptoms on four negative affect measures–anxiety, worry, being down and depressed, and showing a lack of interest or pleasure in doing things, as indicated by responses to the following questions:

Over the last 2 weeks, how often have you been bothered by:

  1. feeling nervous, anxious, or on edge?

  2. not being able to stop or control worrying?

  3. by feeling down, depressed, or hopeless?

  4. bothered by having little interest or pleasure in doing things?

Answers were coded as Not at all = 1, Several days = 2, More than half the days = 3 and Nearly every day = 4.

These are Questions 7 to 10 in S1 Appendix. The S1 Appendix also provides the weighted percentages for each response category.

The four variables follow similar time series paths. Following Blanchflower and Bryson [6] in Fig 2 we plot a composite score which sums these four variables and runs from four to sixteen where 4 would be scored if the respondent answered “Not at all” to all four items whereas 16 would be scored by responding “Nearly every day” on all four. It has a weighted mean of 7.54. It shows a sharp pick up in weeks #49 (September 14–26, 2022) and #50 (October 5–17, 2022) and then a subsequent decline. Referring back to Fig 1 this seems to be associated with the peak in deaths at the end of August 2022.

Fig 2. Composite negative affect index, April 2020-January 2023.

Fig 2

The first four rows of Table 4 report mean scores for the four separate affect variables, together with the composite index in row 5 (labelled “Combined”), for those with who have never had COVID (column 1), those who have had short COVID at some point (column 2), those who had long COVID in the past, and those who were experiencing long COVID at the time of the survey.

Table 4. Raw mean scores for negative affect variables and mobility and cognizance variables by having long or short COVID–n = 454,706.

No covid Short COVID Had long COVID Long COVID now
Panel A:
Anxious 1.94 1.87 2.28 2.53
Down & depressed 1.76 1.66 1.99 2.25
Worry 1.86 1.78 2.14 2.42
Interest 1.79 1.68 2.02 2.30
Combined 7.43 7.06 8.48 9.61
Panel B:
Mobility 1.37 1.23 1.36 1.60
Self-care 1.12 1.07 1.12 1.21
Understand 1.11 1.07 1.12 1.20
Remember 1.49 1.44 1.68 1.96

The table below shows their incidence in the data:

Weighted %
Never had COVID 52.4
Short COVID: COVID but not long COVID 33.2
Had long COVID no symptoms now 7.5
Had long COVID with current symptoms 6.9

It is apparent that there is little difference in the negative affect experienced by those who had never suffered from COVID and those who had only experienced short COVID. However, those who had ever experienced long COVID experienced greater negative affect, particularly if they were currently experiencing long COVID.

In Panel B of Table 4 we report mean scores for mobility difficulties (‘difficulty walking or climbing stairs’ (Q11), difficulties with self-care such as washing or dressing (Q12), understanding or being understood (Q13) and difficulties remembering or concentrating (Q14). In each case, these difficulties are coded from 1 (“No difficulty”) to 4 (“Cannot do at all”). In all cases the same pattern is apparent: physical and mental difficulties are greater for those who had experienced long COVID, particularly those currently experiencing it.

In Table 5 we run ordered logit regressions to estimate the association between COVID status and the four negative affect ordered outcomes, controlling for other factors. The last column reports OLS estimates from the (4,16) continuous outcome based on the summed total of the four negative affect variables. The distribution of this variable is as follows weighted percent—4 = 31.0%; 5 = 8.5; 6 = 9.4; 7 = 8.3; 8 = 12.4; 9 = 5.4; 10 = 4.6; 11 = 3.3; 12 = 4.1; 13 = 2.6; 14 = 2.5; 15 = 2.0 and 16 = 5.9.

Table 5. Regression estimates for 5 negative affect measures.

Anxious Down Worry Interest Combination (OLS)
Short COVID -.2677 (39.47) -.3095 (42.94) -.2587 (36.82) -.3051 (42.54) -.5609 (48.09)
Long COVID not now .3168 (25.91) .2557 (20.23) .3236 (26.10) .2884 (22.98) .5691 (26.13)
Long COVID now .7943 (66.29) .7417 (60.92) .7525 (62.43) .7924 (65.52) 1.6261 (76.76)
Male -.4073 (66.51) -.1775 (27.56) -.4539 (71.50) -.0815 (12.74) -.4515 (42.89)
In paid work -.2119 (28.62) -.3268 (42.23) -.2436 (32.12) -.3187 (41.44) -.6001 (47.42)
/cut1 -1.5064 -1.0877 -1.2179 -1.0989 9.7357
/cut2 .1401 .5004 .3513 .4309
/cut3 .9109 1.2902 1.1253 1.3203
Pseudo/Adjusted R2 .0513 .0414 .0490 .0416 .1227
N 400,360 399,790 399,738 399,589 398,246
Mean dependent variable 2.05 1.78 1.90 1.81 7.15

Notes: In columns 1–4 ordered logits are run given the ordinal nature of the dependent variables. They are 4-step variables running from ‘not at all’ to ‘nearly every day’. The 3 cut-points in the table are coefficients estimated by the model showing where the latent variable underlying the distribution of the dependent variable is cut to make 4 categories. The final column is an Ordinary Least Squares estimator which is appropriate for modelling the continuous additive scale. Controls are age, education, race, state, and week of interview.

The focus is the four-way COVID status variable at the top of the table. The base reference category is the half of individuals who have never had COVID. The three states in the table are having had short COVID only, having had long COVID but not currently suffering symptoms and finally those with long COVID and current symptoms.

In Table 5, because of the way the data is coded, a higher number implies worse mental health. In all five cases the pattern is the same: short COVID has a negative coefficient versus the excluded category of no COVID. Having long COVID is worse especially with current symptoms. The male coefficient is interesting in its own right, confirming that males are less likely to suffer from negative affect that females, confirming earlier work [23]. Working is negatively correlated with negative affect.

4.4: The impact of long COVID on wellbeing among the vaccinated and unvaccinated

In Section Two we reviewed evidence indicating vaccination reduced the likelihood of long COVID. But does it affect individuals’ wellbeing? Bagues and Dimitrova [17] found that having been vaccinated raised well-being using UK data.

In our data we found little difference in vaccine rates across our four COVID states. 84.2% of those who have never had COVID had been vaccinated, although we don’t know how many shots they have had. This compares with 82.0% of those with short COVID; 81.2% for those with long COVID but not presently with symptoms and 83.1% of those with long COVID now and 83.2% overall. As regards the link between vaccination and wellbeing we find similar results to Bagues and Dimitrova [17] although the extent of the wellbeing improvement varies across our four COVID type categories.

Below we show using the weeks #46-#53 data, that anxiety is higher if the respondent had not been vaccinated. The biggest differences are for those reporting anxiety nearly every day. Even among those who have had a vaccine and never had COVID 14% are anxious nearly every day versus 22% who had not been vaccinated. Results are similar using the other three affect variables.

Anxious No vaccine Vaccinated
Non COVID
Not at all 39 42
Several days 27 32
More than half the days 12 11
Nearly every day 22 14
Short COVID
Not at all 39 43
Several days 32 35
More than half the days 12 11
Nearly every day 17 12
Long COVID not now
Not at all 26 26
Several days 33 38
More than half the days 16 15
Nearly every day 24 22
Long COVID now
Not at all 17 17
Several days 30 35
More than half the days 16 17
Nearly every day 37 31

4.5: The impact of long COVID on aspects of daily life

Table 6 estimates equivalent equations to those in Table 5 but this time for four other potential outcomes of long COVID. The first two are difficulty walking or climbing stairs, what we term ‘mobility’ (column 1), and difficulties with self-care such as washing or dressing (column 2) while the other two relate to cognition—difficulties remembering or concentrating (column 3) and difficulties understanding or being understood (column 4). The pattern of results is identical to those presented in Table 5: compared to those who had never had COVID, short COVID is better than no COVID, whereas long COVID especially with current symptoms generates a significantly higher probability of facing the two physical and two mental health difficulties.

Table 6. Ordered logit estimates, physical mobility, remembering and understanding.

Mobility. Dressing & bathing Remember Understand
Short COVID -.3135 (33.00) -.4509 (28.00) -.1560 (20.76) -.3970 (23.81)
Long COVID not now .3115 (19.39) .1003 (4.01) .5660 (42.66) .2302 (9.28)
Long COVID now .9845 (70.39) .7193 (35.61) 1.3400 (102.45) .9142 (45.57)
Male -.2706 (33.23) .0638 (4.84) -.2657 (39.51) +.3006 (22.42)
In paid work -.7121 (78.13) -1.1444 (76.55) -.2871 (35.60) -.5967 (38.79)
/cut1 1.1459 .6125 -.9711 .3511
/cut2 3.1538 2.6589 1.6389 2.7177
/cut3 5.6540 4.5017 5.1847 4.4657
Pseudo R2 .1210 .0698 .1420 .0544
N 390,904 390,999 388,552 391,058
Mean dependent variable 1.34 1.11 1.52 1.10

Notes: Controls are age, education, race, state, and week of interview.

The possibility exists that some of the impact of long COVID on mobility and cognition could arise due to poor mental health. Indeed, there is evidence from Wang et al. [24] that prior psychological distress before SARS-CoV-2 infection is associated with risk of COVID–related symptoms lasting 4 weeks or longer. Hence Table 7 uses the same four outcomes as in Table 6 but now also includes the mental health score as a control variable which is the sum of the negative affect variables. Unsurprisingly, scoring high on mental health problems is associated with problems with mobility, dressing and bathing, remembering and understanding. However, even though its incorporation results in a decline in the size of the coefficients attached to COVID the COVID variables are of the same sign as in Table 6 and remain highly statistically significant.

Table 7. Ordered logit estimates, physical mobility, remembering and understanding and mental health.

Mobility. Dressing & bathing Remember Understand
Short COVID -.2163 (22.17) -.3048 (18.01) -.0163 (2.04) -.2534 (14.76)
Long COVID not now .2423 (14.68) -.0007 (0.03) .4894 (35.22) .1348 (5.25)
Long COVID now .7609 (52.92) .4072 (19.23) 1.0651 (79.15) .6299 (30.13)
Male -.2114 (25.31) .1467 (10.72) -.1747 (24.55) +.4036 (29.11)
In paid work -.6366 (68.18) -1.0206 (66.12) -.1675 (19.72) -.4458 (28.17)
Combination mental health score .1757 (146.72) .2235 (128.91) .2700 (239.22) .2099 (119.09)
/cut1 3.0046 3.0017 1.4758 2.5060
/cut2 5.1281 5.1375 4.4989 4.9476
/cut3 7.6937 7.0153 8.1891 6.7211
Pseudo R2 .1604 .1442 .1420 .1221
N 388,586 388,597 388,552 388,729

Notes: Controls are age, education, race, state, and week of interview.

5. Conclusions

We have exploited new data for nearly half a million Americans on the prevalence of long COVID to explore its incidence and correlates, and the relationship between long COVID and physical and mental health problems. Long COVID is widespread. It has affected 14 percent of Americans at some point.

Its incidence varies markedly across sub-groups in the population. It is much higher among women than it is among men; it varies by ethnicity, being highest among whites; and it is hump-shaped in age, mimicking the age profile of negative affect which is highest in middle age. It also varies greatly by location. It is highest in states in the south such as West Virginia and Mississippi–states where negative affect is high–and is lowest in Hawaii, notable for being the ‘happiest’ state in the United States.

Long COVID is independently associated with negative affect, however one measures it, and with physical mobility and mental health problems. These associations are strongest among those who report current symptoms of long COVID.

Notwithstanding these new findings much remains to be learned about the nature, determinants and consequences of long COVID which will only be revealed in time with the advent of new data. In particular, exploiting longitudinal data tracking individuals over time could be particularly informative since in the current study the cross-sectional nature of the data makes it hard to make causal inferences about the impact of Long COVID and the potential value of vaccinations.

Supporting information

S1 Appendix. Questions used to identify long COVID–with weighted percentages in square parentheses.

(DOCX)

Data Availability

The data can be acquired via the US Census Bureau. The data are publicly available and can be downloaded here: https://www.census.gov/programs-surveys/household-pulse-survey/datasets.html. The accompanying technical documentation can be found here: https://www.census.gov/programs-surveys/household-pulse-survey/technical-documentation.html.

Funding Statement

The authors received no specific funding for this work.

References

Decision Letter 0

Kanchan Thapa

4 May 2023

PONE-D-23-04744Long COVID in the United StatesPLOS ONE

Dear Dr. Bryson,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please organize the paper in standard PLOS one format and review additional papers on the same field. Use appropriate referencing throughout the paper. 

Please submit your revised manuscript by Jun 18 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kanchan Thapa, MPH, MPhil

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods section, please include additional information about your dataset and ensure that you have included a statement specifying whether the collection and analysis method complied with the terms and conditions for the source of the data.

3. Thank you for stating the following financial disclosure:

“NO - Include this sentence at the end of your statement: The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript”

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Additional Editor Comments:

Dear authors,

I enjoyed reading your paper. I suggest you to revise your paper adhering to reviewer’s comment and also with the following suggestions:

1. Please include the referencing of each item that you have cited in the paper. Without referencing, we can’t move ahead

2. Please organize your paper in the simple, scientific, fluent, and understandable language

3. Please follow the format of a standard research paper while organizing your paper

4. It seems like you have uploaded the draft version of the paper, so I suggest you to upload the final version of the paper clearly stating: background, methods, results, discussion/ conclusion section. I suggest you to review additional paper on PLOS One for details.

5. Try to improve your paper based on reviewer I.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: the article is well written

age description and distribution among tables are not unified

it would have been interesting to showcase symptoms vs annual income rate

a comparison between vaccinated vs non vaccinated group would be interesting

Reviewer #2: This is an interesting paper looking at an important topic: long COVID. The paper computes prevalence overall and by demographic and geographical levels. It also describes how long covid is associated with negative affect for different demographic groups and by vaccination status.

In my view, the paper is too difficult to read and it is therefore complicated to understand how sound the description is. The paper generally lacks context and depth in discussing the findings by subgroups and is not suited for an international multidisciplinary audience.

The definition of short and long covid is not given.

Data are described with sweeps only instead of giving the corresponding period covered.

Literature review unclear:

-Regarding Ayoubkhani's findings (page 2), it is unclear whether the second dose was less effective than the first dose. This needs be clarified or rephrased if necessary.

- On page 4, the authors claim that their results are consistent, but they only cite one study without providing context. Was this study also conducted in the US ?

The presentation of tables and charts are challenging:

Table 3 raises the question of whether certain groups were excluded from the analysis. It is unclear if these excluded groups are the reference categories or if they were excluded for other reasons. For example, what is happening with the 89 years old and over category if those under 20 are the reference category? The layout of the tables is poor and the discussion of the construction of the results presented in the tables is so absent that it is difficult to assess the reliability of the interpretation made in the main text.

What is the sample size in Table 4?

Chart 1 plots numbers. There is no context neither on the chart nor in the text.

No URL for data availability. Manuscript submission requirements were not met, eg. double spacing, footnotes etc. No line numbers to refer to for comments.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 2;18(11):e0292672. doi: 10.1371/journal.pone.0292672.r002

Author response to Decision Letter 0


13 Jun 2023

PONE-D-23-04744

Long COVID in the United States

PLOS ONE

13th June 2023

Dear Dr. Kanchan Thapa,

Thank you for giving us the opportunity to revise our manuscript for PLOS ONE.

This is our letter responding to each point raised by the academic editor and reviewers. We also attach a marked-up copy of our manuscript that highlights changes made to the original version together with an unmarked version of our revised paper without tracked changes.

We have tried to meet PLOS ONE's style requirements, including those for file naming.

In our section entitled “Data and Methods” we have included additional information about the dataset and how to access it.

You have asked us to clarify the sources of funding (financial or material support) for your study. There were none. So we can confirm that we received no funding for this project.

The referencing now follows the standard approach in PLOS ONE with numerical indicators in squared brackets pointing to the relevant reference in the bibliography.

In terms of style and content we have organised the paper in a simple fashion adopting the structure that is standard in PLOS ONE. In doing so we have modified our language to make it more scientific, fluent and direct.

The sections are now formatted in a way that is standard for PLOS ONE papers.

Below we outline how we have responded to the reviewers’ comments. Our responses are in underlined bold italics.

Reviewer #1

1. The article is well written

RESPONSE: Thank you.

2. age description and distribution among tables are not unified

RESPONSE: We wish to retain the differences in the age classifications in Tables 2 and 3. Table 2 is more aggregated because we are providing a descriptive overview but we want to be more granular in Table 3 in the regression analysis.

3. it would have been interesting to showcase symptoms vs annual income rate

RESPONSE: Although this additional analysis could be interesting the paper is quite long already so we don’t think there is much room for additional heterogeneity analysis. Instead we have focused on key differences, namely when the respondent had long COVID and the extent of the symptoms and the role of the vaccine.

4. a comparison between vaccinated vs non vaccinated group would be interesting

RESPONSE: Again, this is something one could have added, but it isn’t central to our concerns which are about the correlates of long COVID – including vaccine receipt - and the association between long COVID and wellbeing outcomes. Given the length of the paper we have chosen to omit analysis of differences between those who have been vaccinated and those who have not.

Reviewer #2

This is an interesting paper looking at an important topic: long COVID. The paper computes prevalence overall and by demographic and geographical levels. It also describes how long covid is associated with negative affect for different demographic groups and by vaccination status.

In my view, the paper is too difficult to read and it is therefore complicated to understand how sound the description is. The paper generally lacks context and depth in discussing the findings by subgroups and is not suited for an international multidisciplinary audience.

RESPONSE: We have tried to simplify the structure and language.

The definition of short and long covid is not given.

RESPONSE: We provide a definition of long COVID in paragraph 2 but return to the issue in the literature review pointing out that definitions vary a little across studies. Appendix 1 details the questions used in our data to define long COVID. We define short COVID as having COVID symptoms for less than 3 months.

Data are described with sweeps only instead of giving the corresponding period covered.

RESPONSE: We provide dates for each sweep in footnote 1 and provide dates in various places.

Literature review unclear:

-Regarding Ayoubkhani's findings (page 2), it is unclear whether the second dose was less effective than the first dose. This needs be clarified or rephrased if necessary.

RESPONSE: The authors do not speculate as to whether a second dose was less effective than the first. Instead, they couch their findings in terms of the second dose sustaining the protection against long COVID. We have added a phrase in to that effect.

- On page 4, the authors claim that their results are consistent, but they only cite one study without providing context. Was this study also conducted in the US?

RESPONSE: The other paper is also for the USA. We now make this clear in the text.

The presentation of tables and charts are challenging:

Table 3 raises the question of whether certain groups were excluded from the analysis. It is unclear if these excluded groups are the reference categories or if they were excluded for other reasons. For example, what is happening with the 89 years old and over category if those under 20 are the reference category? The layout of the tables is poor and the discussion of the construction of the results presented in the tables is so absent that it is difficult to assess the reliability of the interpretation made in the main text.

RESPONSE: The ‘excluded’ categories are indeed the reference groups for the regression. The footnote has been revised to make this clear. There is nobody over the age of 89.

What is the sample size in Table 4?

RESPONSE: Sample size is 454,706 which has been added to the tabl

Chart 1 plots numbers. There is no context neither on the chart nor in the text.

RESPONSE: The Chart (relabelled Fig. 1) provides context by showing the incidence of COVID cases and deaths reported each week for the U.S. by the CDC. The figure is described in the first paragraph. We have relabelled the figure so it is clear what is being presented.

No URL for data availability.

RESPONSE: the URL for the data is now provided. It is publicly available.

Manuscript submission requirements were not met, eg. double spacing, footnotes etc. No line numbers to refer to for comments.

RESPONSE: The main text is now double spaced and all footnotes have been removed and line numbers added.

Decision Letter 1

Kanchan Thapa

25 Jul 2023

PONE-D-23-04744R1Long COVID in the United StatesPLOS ONE

Dear Dr. Bryson,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I am echoing with reviewer comments. Please revise the paper based on their comments. Also, review, revise and resubmit. Please also make changes based on previous rounds of comments by reviewers. 

Please submit your revised manuscript by Sep 08 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kanchan Thapa, MPH, MPhil

Academic Editor

PLOS ONE

Additional Editor Comments:

Dear Authors,

I enjoyed reading your revised paper. Reviewing the paper and echoing with reviewers, I would like to request you to revise the tables and take care of the comments raised in before too. Authors should address each comments properly especially those raised on Table and interpretation section. Following the second round of review too, a reviewer made similar comments on interpretation and table. Please revise and resubmit the paper.

Be consistent with the authors who contributed the paper? List all the authors in the system.

Similarly, authors mentioned COVID throughout the paper. Is there any difference between COVID 19 and COVID? IS there any competing interest to mention COVID-19 by the authors? Please also ensure both authors read the paper, revise based on your review and submit the paper.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

Reviewer #4: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

Reviewer #4: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

Reviewer #4: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: This revised manuscript is well written and addresses prevalence of long COVID in different level, i.e., demographic and geographical levels, as well as the relationship between long COVID and physical and mental health problems.

Compared to the original manuscript, it is more organized and well presented.

Reviewer #4: The findings as presented in the tables are difficult to interpret at best. It appears to omit key, usual statistical output. The presentation of the tables are lacking, e.g. identification of what is presented and of measures of statistical significance.

What are the authors' views about their findings? - e.g., on short COVID associated with least MH and well-being risk? Why are those who are middle age and female most affected?

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: PLOS Jul23.docx

PLoS One. 2023 Nov 2;18(11):e0292672. doi: 10.1371/journal.pone.0292672.r004

Author response to Decision Letter 1


28 Jul 2023

PDF Page, Line Comment Response

43 - Abstract It “peaks in midlife” -Can we refer to long covid as peaking given the relatively short duration of this event, not allowing for an appropriate follow-up period? “peaks in midlife” has been replaced with “is at its highest in midlife”.

45, 28 The paragraph in the Introduction is a repeat of the Abstract. What’s the purpose? Here again is the phrase about peaking in midlife. The purpose is simply to summarise the paper and its results in the main body of the text early on. “peaks in midlife” has been replaced with “is at its highest in midlife”.

45, 33-34 “The effect is larger …” What is being referred to here, is it long COVID (LC)? And which groups are being compared? Is it the effect of LC is larger among people who currently report LC compared to those who experienced LC in the past? “The effect is larger” has been replaced by “with the correlation being strongest among those who currently report long COVID, especially if they report severe symptoms”.

46, 48-50 Italics and quotation marks are not used in a consistent way. Quotations are no longer italicised

46, 55 The authors’ recap of O’Mahoney et al’s findings – is ‘COVID-19 survivors’ the same as anyone who had COVID? Yes that’s what it means. We have left it unchanged because it seems clear from the text.

46, 62-63 Results of Taquet are confusing – was a larger proportion of survivors (57%) affected after 180 days than in the earlier period (37% in 90 to 180 days)? The sentence has been rephrased to read “57% of patients having at least one long-COVID feature recorded within the first 180 days after infection and 37% having them in the 90 to 180 days after diagnosis”

46, 65 > (paragraph) Is there a reason for this paragraph to be written in the present tense? The paragraph has been revised so that it uses the past tense.

47, 79 >

47, 84 Rather than per population, could we report on the per cent of the survivors with long COVID?

‘They adversely impacted …’ is ‘they’ referring to long COVID? The earlier use of ‘they’ in that paragraph referred to the Office of National Statistics. They express the incidence relative to the population so this is what we report.

We have revised the text to read “Long COVID symptoms adversely impacted the day-to-day activities of 1.6 million”. Thank you for spotting this.

52, 185 till Wed

59, 345 Is this a table of results from the current study? The content focuses on anxiety. However, I do not recall details about the measure of anxiety and how the scores are interpreted in the Methods section. 58, 318 – seems to be referring to mental health data and coding, which should be expanded in the Methods. Yes the table is from our own analysis. The details of the anxiety measure are provided a little earlier in the article and are replicated here for reference. We use a) for anxiety from the following question:

Over the last 2 weeks, how often have you been bothered by:

a) feeling nervous, anxious, or on edge?

b) not being able to stop or control worrying?

c) by feeling down, depressed, or hopeless?

d) bothered by having little interest or pleasure in doing things?

Answers were coded as Not at all =1, Several days =2, More than half the days=3 and Nearly every day=4.

Rather than having a very lengthy methods section incorporating all questions we have decided to report them as we present our results, so that the reader finds it easier to refer to them when absorbing the results.

59, 342 Is the 15% referring to the 14% in the data presented on anxiety? … in the ‘non COVID’ group. Thank you for spotting this. The text has been revised to read: “Even among those who have had a vaccine and never had COVID 14% are anxious nearly every day versus 22% who had not been vaccinated”

60, 374 “The four long COVID categories each have positive signs..” unclear what this means. Thank you for this. We have clarified the meaning of the sentence by rephrasing it as follows: “Having long COVID now, or in the past, is associated with higher negative affect compared to having no COVID and no vaccine but among those with long COVID now or in the past, negative affect was always lower if they had had the vaccine.”

Table 5 Notes – it is unclear what is meant by ‘age dummies’ and in subsequent tables ‘Working/cut1/ cut2 etc. These are not explained or described. The word “dummies” has been dropped from all table footnotes so that we now refer to controlling for age. “Working” has been replaced by “In paid work” to denote the respondent’s labour market status. Cut1/cut2/cut3 are part of the standard output from an ordered probit regression so these are retained

Table 6 – conventional formatting of this and other tables might help the reader to understand what is being presented. The models are presented in a conventional fashion. We assume that the comments and changes above clarify what is presented.

Chart 1 differ from Figure 1? We only refer to Figure 1 now. There is no Chart 1

61, 389 Isn’t the reference to Wang et al discussing what this paper defines as ‘long COVID’? What is ‘post-COVID-19 conditions” and is the ‘?’ a typo? We have clarified what the sentence means so it reads: “There is evidence from Wang et al. [24] that prior psychological distress before SARS-CoV-2 infection is associated with risk of COVID–related symptoms lasting 4 weeks or longer.”

Thanks yes the question mark was a typographical error.

61-62 The authors’ interpretation of the findings is not provided; there is no Discussion. The Conclusions section provides a summary of the findings. Yes, we simply summarise the findings from our study in the conclusion because these are new findings about the prevalence, correlates and wellbeing-related outcomes linked to long-COVID which are not well-documented. However, we have added the following sentence: “Notwithstanding these new findings much remains to be learned about the nature, determinants and consequences of long COVID which will only be revealed in time with the advent of new data.”

Decision Letter 2

Kanchan Thapa

21 Sep 2023

PONE-D-23-04744R2Long COVID in the United StatesPLOS ONE

Dear Dr. Bryson,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please address the comments from the reviewers. 

Please submit your revised manuscript by Nov 05 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kanchan Thapa, MPH, MPhil

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

Dear Authors,

Please address the few more changes requested by peer reviewers.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #5: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #5: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #5: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #5: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #5: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: please amend line 371: what is "comp"?

Please mention in titles when tables are only descriptive (like Table 4). The way it currently stands, we are not sure what Table 4 is, they should be self explanatory.

Could people with long covid had their vaccination after getting long covid? If so, I dont know what to do with all the vaccination part. If people get vaccinated (or not) because of getting long covid, splitting the sample by vaccination status does not seem to bring additional information.

I agree with the other reviewer that the standard output from ordered logit such as cut1 cut2 etc need to be explained at least in the table notes .

People who dont get COVID may be comprised of those who got out, some of which got covid, and people who didnt get out and didnt get covid. This would explain why those who didnt get covid seem worse off. I wonder if potential explanations for the results could go in the conclusion or discussion. The paper generally lacks a section on limitation.

Reviewer #5: Summarize the second paragraph of introduction part and merge it with first paragraph of introduction part (Long Covid Definition).

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #5: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Nov 2;18(11):e0292672. doi: 10.1371/journal.pone.0292672.r006

Author response to Decision Letter 2


22 Sep 2023

Dear Editor

Response to Reviewers PONE-D-23-04744R2 “Long COVID in the United States”

We thank you for giving us a further opportunity to revise the paper. Below we explain in bold italics how we have responded to the points made by the reviewers.

Reviewer #2:

please amend line 371: what is "comp"?

Thank you for spotting this error. We have revised the text accordingly.

Please mention in titles when tables are only descriptive (like Table 4). The way it currently stands, we are not sure what Table 4 is, they should be self explanatory.

We have amended the table title accordingly.

Could people with long covid had their vaccination after getting long covid? If so, I dont know what to do with all the vaccination part. If people get vaccinated (or not) because of getting long covid, splitting the sample by vaccination status does not seem to bring additional information.

We have removed table 6 accordingly, together with the attendant text and comments in the conclusion.

I agree with the other reviewer that the standard output from ordered logit such as cut1 cut2 etc need to be explained at least in the table notes .

We have extended the table notes accordingly.

People who dont get COVID may be comprised of those who got out, some of which got covid, and people who didnt get out and didnt get covid. This would explain why those who didnt get covid seem worse off. I wonder if potential explanations for the results could go in the conclusion or discussion. The paper generally lacks a section on limitation.

We have noted the limitations to our paper due to the cross-sectional nature of the data and indicated why advances in knowledge could come from longitudinal data tracking individuals over time. In the absence of such data we have decided not to speculate about the relative mental health of those who don’t get COVID versus those who get short COVID.

Reviewer #5

Summarize the second paragraph of introduction part and merge it with first paragraph of introduction part (Long Covid Definition).

We have merged these paragraphs together.

Decision Letter 3

Kanchan Thapa

27 Sep 2023

Long COVID in the United States

PONE-D-23-04744R3

Dear Dr. Bryson,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kanchan Thapa, MPH, MPhil

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Kanchan Thapa

6 Oct 2023

PONE-D-23-04744R3

Long COVID in the United States

Dear Dr. Bryson:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Mr. Kanchan Thapa

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Appendix. Questions used to identify long COVID–with weighted percentages in square parentheses.

    (DOCX)

    Attachment

    Submitted filename: PLOS Jul23.docx

    Data Availability Statement

    The data can be acquired via the US Census Bureau. The data are publicly available and can be downloaded here: https://www.census.gov/programs-surveys/household-pulse-survey/datasets.html. The accompanying technical documentation can be found here: https://www.census.gov/programs-surveys/household-pulse-survey/technical-documentation.html.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES